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benzylamine-N2-isopropyl-quinazoline-2,4-
diamines derivatives as potential antibacterial
agents
Zhengyun Jiang,a W. David Hong,bcde Xiping Cui,a Hongcan Gao,a Panpan Wu,ad
Yingshan Chen,a Ding Shen,a Yang Yang,a Bingjie Zhang,a Mark J. Taylor,b
Stephen A. Ward,b Paul M. O'Neill,c Suqing Zhao *a and Kun Zhang*ade
A series of N4-benzylamine-N2-isopropyl-quinazoline-2,4-diamine derivatives has been synthesized and tested
for antibacterial activity against ﬁve bacterial strains. Twelve diﬀerent substituents on the N4-benzylamine group
have been investigated along with replacement of the quinazoline core (with either a benzothiophene or
regioisomeric pyridopyrimidine ring systems). In order to develop structure activity relationships, all derivatives
were tested for their antibacterial activities against Escherichia coli and Staphylococcus aureus via Kirby–
Bauer assays and minimum inhibitory concentration assays. Eight of the most potent compounds against S.
aureus and E. coli were also screened against one strain of methicillin-resistant S. aureus (MRSA),
Staphylococcus epidermidis and Salmonella typhimurium to further examine their antibacterial activities. Lead
compound A5 showed good activities with MICs of 3.9 mg mL1 against E. coli, S. aureus and S. epidermidis
and 7.8 mg mL1 against MRSA. Selected front runners were also screened for their DMPK properties in vitro
to assess their potential for further development.Introduction
Novel antibacterial chemotypes are urgently needed because of
the emergence and spread of multidrug resistant microorgan-
isms and pathogenic bacterial infections.1,2 Staphylococcus
aureus is the most common pathogen of surgical site and
wound infections.3–6 Antibiotic-resistant strains of S. aureus
infections oen occur in epidemic waves that are initiated by
one, or a few, successful clones.7–9 Every year in the United
States approximately two million people fall ill and 23 000
people die because of antibiotic-resistant bacterial infections,
according to a report from the Center for Diseases Control and
Prevention.10,11 Antibiotic-resistant bacterial strains, in partic-
ular methicillin-resistant S. aureus (MRSA) infection rates
remain constant within the community and hospital settings in
U.S.12–14 Worryingly, strains of S. aureus showing extended
resistance to vancomycin, daptomycin, linezolid andSchool of Chemical Engineering and Light
ogy, Guangzhou, 510006, China. E-mail:
, Department of Parasitology, Liverpool
QA, UK
rpool, Liverpool, L69 7ZD, UK
ngineering, Wuyi University, Jiangmen,
te (Jiangmen), Jiangmen, 529000, China
hemistry 2017cearoline, which are used to treat MRSA infections, have been
reported recently in the literature.15–18 MRSA is on the list of
bacteria for which new antibiotics are urgently needed as
recognized by World Health Organization in 2017.19
Quinazolines and derivatives have shown attractive antibacte-
rial activity.20–22 In previous studies, quinazoline-based compounds
have been investigated for their potential antibacterial activity,
especially anti-MRSA activity. Bedi et al. (2004) reported 2,4-
disubstituted quinazoline, such as compound A (Fig. 1), displayed
antibacterial activity against a wide spectrum of bacteria including
S. aureus, and E. coli.23 Chandrika et al. (2010) reported the in vitro
activity of multiple uoro-substituted triazol-4-yl substituted qui-
nazoline B (Fig. 1) against S. aureus and S. epidermidis with anMIC
of 9.375 mg mL.24 Van Horn et al. (2014) have reported N2,N4-
disubstituted quinazoline-2,4-diamines such as C (Fig. 1) thatFig. 1 Quinazolines with reported antibacterial activity.
RSC Adv., 2017, 7, 52227–52237 | 52227
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View Article Onlinedisplayed in vitro and in vivo activities against S. aureus, a low
potential for spontaneous resistance and low toxicity.25 Further-
more, this proof-of-concept work opened up opportunities for
further investigation of quinazoline-2,4-diamines in terms of
structural activity relationships against a broader spectrum of
bacteria strains and DMPK related parameters. In this work, we
designed a library of 2,4-diaminoquinazoline analogues and
closely related derivatives, including thirteen 2,4-dia-
minoquinazolines, thirteen 2,4-diaminothieno[3,2-d]pyrimidines,
six 2,4-diaminopyrido[3,2-d]pyrimidine derivatives and six 2,4-
diaminopyrido[2,3-d]pyrimidine derivatives. These compounds are
structurally distinct from previously reported quinazoline core
antibacterials. These compounds have been used to further
explore how the structural variation aﬀects antibacterial activity.
Herein, a structure–activity relationship (SAR) study is reported
which focuses on the substituent of N4-benzylamine and the
variations of the quinazoline scaﬀold.
All derivatives were tested against S. aureus and E. coli in
Kirby–Bauer assays initially. The antibacterial potency of active
compounds was further determined by minimum inhibitory
concentrations (MICs) assays. Further MICs assays were per-
formed against methicillin-resistant S. aureus (MRSA), Staphy-
lococcus epidermidis and Salmonella typhimurium to evaluate the
spectrum of antibacterial activity of themost active compounds.
In addition, DMPK related properties, such as lipophilicity
(log D7.4), aqueous solubility and in vitro metabolic stability
were also assessed for a selected group of compounds to illus-
trate how the structural modications can potentially inuence
the pharmacokinetics of these new lead molecules.Results and discussion
Chemistry
To systematically explore structure–activity relationships,
a group of N4-benzylamine-N2-isopropyl-quinazoline-2,4-
diamine derivatives which include four chemical subsets ofFig. 2 Synthetic route and chemical structures of N4-benzylamino-N2-i
POCl3, 120 C, 6 h; (II) substituted benzylamine, triethylamine, THF, rt, o
52228 | RSC Adv., 2017, 7, 52227–52237compounds with diﬀerent heterocyclic aromatic rings fused to
the pyrimidine ring in the scaﬀold were designed and then
subsequently synthesized via adapted methods from the liter-
ature (Fig. 2).25–30 Commercially available compound (a) was
reacted with phosphorus oxychloride and phosphorus penta-
chloride resulting in the corresponding 2,4-dichloro interme-
diates (b). Substitution with benzylamines occurred selectively
at the 4-position, yielding 4-benzylamino-2-chloroquinazoline
(c) under mild conditions. Next, substitution at the 2-position
with isopropyl amine gave the desired 2,4-diamino products (d).
The synthesis of compounds from series A and B were started
from the commercially available as quinazoline-2,4(1H,3H)-
dione and thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione, respec-
tively. However, 2,4-dichloropyrido[3,2-d]-pyrimidine and 2,4-
dichloropyrido[2,3-d]pyrimidine, exemplied as intermediate
(b) which were readily acquired commercially have been used in
the synthesis of series C and D compounds. Throughout the
synthetic routes, all intermediates have been puried and the
nal N4-benzylamine-N2-isopropyl-quinazoline-2,4-diamines
derivatives have been characterized by 1H NMR, 13C NMR and
high resolution mass spectrum.Structure–activity relationship study
Initially all 4 chemical subsets (series A–D) were tested for their
activities in inhibiting bacterial growth in the Kirby–Bauer assay
against E. coli and S. aureus. Active compounds with zones of
inhibitions (ZOIs)$ 7.0 mm in the Kirby–Bauer assay were then
tested for their minimum inhibitory concentrations (MICs) to
quantify their potency against E. coli and S. aureus (Table 1). The
data of ZOIs and MICs presented are the average results from
three independent experiments.Kirby–Bauer assay
Kirby–Bauer assay was used to test the compounds at a single
concentration of 5 mg mL1 to determine whether theysopropyl-quinazoline-2,4-diamines. Reagents and conditions: (I) PCl5,
vernight; (III) isopropylamine, 1,4-dioxane, 120 C, 48 h.
This journal is © The Royal Society of Chemistry 2017
Table 1 Antibacterial activities of N2-isopropyl-N4-benzylamine-quinazoline-2,4-diamines derivatives
Compound code R
E. colia S. aureusb
ZoIs (mm) MICs (mg mL1) ZoIs (mm) MICs (mg mL1)
A1 4-CN–phenyl– 20.2  0.6 31.2 11.8  0.5 31.2
A2 2-SO2Me–phenyl– 8.3  0.2 125.0 8.1  0.2 62.5
A3 4-SO2Me–phenyl– 7.5  0.3 $125.0 None NT
A4 2-CF3–phenyl– 20.4  0.7 15.6 16.2  0.7 3.9
A5 4-CF3–phenyl– 22.4  0.1 3.9 13.2  0.5 3.9
A6 2-F–phenyl– 23.8  0.8 15.6 12.4  0.3 15.6
A7 4-F–phenyl– 22.3  0.5 15.6 14.5  0.3 7.8
A8 2-Cl–phenyl– 21.2  0.7 15.6 12.0  0.5 3.9
A9 4-Cl–phenyl– 18.6  0.2 7.8 11.6  0.2 3.9
A10 2-OCH3–phenyl– 15.7  0.6 31.2 17.4  0.5 31.2
A11 4-OCH3–phenyl– 17.1  0.9 31.2 15.4  0.4 7.8
A12 3,4-Di–OCH3–phenyl– 16.2  0.4 31.2 14.6  0.5 15.6
A13 4-CN–phenyl– 21.0  0.4 31.2 11.6  0.3 31.2
B1 2-SO2Me–phenyl– 7.2  0.1 $125.0 8.9  0.3 62.5
B2 4-SO2Me–phenyl– 7.9  0.2 $125.0 None NT
B3 2-CF3–phenyl– None
c NTd None NT
B4 4-CF3–phenyl– 16.8  0.8 31.2 12.1  0.3 7.8
B5 2-F–phenyl– 8.6  0.1 125.0 12.7  0.3 7.8
B6 4-F–phenyl– 8.0  0.3 62.5 11.1  0.5 31.2
B7 2-Cl–phenyl– 8.5  0.4 62.5 10.9  0.3 31.2
B8 4-Cl–phenyl– 11.4  0.4 62.5 13.6  0.6 15.6
B9 2-OCH3–phenyl– 8.1  0.5 62.5 12.9  0.4 7.8
B10 4-OCH3–phenyl– None NT None NT
B11 3,4-Di–OCH3–phenyl– None NT None NT
B12 4-CN–phenyl– None NT 9.2  0.4 62.5
B13 2-SO2Me–phenyl– 7.3  0.1 $125.0 8.2  0.1 62.5
C1 4-SO2Me–phenyl– None NT 7.6  0.3 62.5
C2 4-CF3–phenyl– None NT None NT
C3 4-CN–phenyl– None NT None NT
C5 2-SO2Me–phenyl– None NT 8.5  0.6 15.6
C13 4-SO2Me–phenyl– None NT None NT
D1 4-CF3–phenyl– None NT None NT
D2 4-CF3–pyridyl– None NT 8.1  0.2 31.2
D3 4-CF3–pyridyl– None NT None NT
D5 4-CF3–pyridyl– None NT 10.2  0.1 7.8
D13 4-CF3–pyridyl– None NT 8.1  0.8 62.5
Noroxacin NT #0.12 NT 0.24
Vancomycin NT >31.2 NT 0.98
Methicillin NT >31.2 NT 0.49
a Escherichia coli, CMCC 44102. b Staphylococcus aureus, ATCC 6538. c No zone of inhibition was determined. d Not tested.
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View Article Onlineinhibited bacterial growth. The data are exhibited in Table 1. In
this assay, sterile lter disks with a diameter of 6 mmwere used.
The diameter of ZOIs greater than 10.0 mm was dened as
strongly active, 7.0–10.0 mm was weakly active, and less than
7.0 mmwas inactive. As shown in Fig. 3, 13 compounds all from
series A or B appear in the green area which signies
compounds showing potent activity against both Gram-negative
bacteria, E. coli and Gram-positive bacteria S. aureus. In the le-
hand side yellow area, 5 compounds from series B and D
showed some activity against Gram-positive S. aureus but weakThis journal is © The Royal Society of Chemistry 2017activity against Gram-negative E. coli. No compound showed
noticeably stronger activity against Gram-negative E. coli than
Gram-positive S. aureus, represented by the blue coloured area
in Fig. 3. From this analysis, it also indicated that while
a number of series A quinazoline analogues have activities
against both Gram-positive and Gram-negative bacteria, series
B thieno[3,2-d]pyrimidines were more biased to Gram-positive
bacteria and series C and D compounds had limited activities
in inhibiting the growth of these bacterial strains.RSC Adv., 2017, 7, 52227–52237 | 52229
Fig. 3 Zones of inhibition (ZOIs) in Kirby–Bauer assays against E. coli
and S. aureus.
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View Article OnlineMinimum inhibitory concentrations (MICs) assay
All N4-benzylamine-N2-isopropyl-quinazoline-2,4-diamines
derivatives with measurable ZOIs in the Kirby–Bauer assays
were tested in minimum inhibitory concentration (MIC) assays
against the same two strains of bacteria to quantitatively
determine their antibacterial potency. Noroxacin, vancomycin
and methicillin were used as positive controls.
In general, the results of the MIC assay mirrored the results
from the single concentration Kirby–Bauer assay, and the
antibacterial potency of the chemical series are in the order of
quinazolines > thieno[3,2-d]pyrimidines > pyrido[3,2-d]pyrimi-
dines z pyrido[2,3-d]pyrimidines, while higher potency was
observed against Gram-positive S. aureus than against Gram-
negative E. coli. (Table 1). In the most active subset, series A,
substitutions on the benzene ring in the N4-benzylamin side-
chain had a signicant eﬀect of the potency of compounds.
Lipophilic electron withdrawing group substitution in this side-
chain, such as CF3 and Cl were benecial for antibacterial
activity. On the other hand, the more polar substitutions i.e.
SO2Me or CN were not tolerated (A1–3). Similar observations
were also seen aer the incorporation of an additional nitrogen
in this side-chain (A13) which reduced both lipophilicity (log D)
and potency compared with the corresponding analogue A5
without the nitrogen (further discussion regarding the eﬀect of
the structural modications to the physiochemical properties
are described in a following session). Series A analogues, with
substitutions at the para-position of the benzene ring, were
more potent against Gram-negative E. coli than the corre-
sponding ortho-substituted analogues, but these substitutions
had little eﬀect on potency against Gram-positive S. aureus (A4
vs. A5 and A8 vs. A9). Quinazoline derivative A5 with a tri-
uoromethyl group at the para-position of the benzene ring was
the most active compound in this subset of compounds and
indeed in this whole set of compounds with MICs ¼
3.9 mg mL1 against both Gram-positive and negative bacteria,
S. aureus and E. coli. It was closely followed by the chloro-
substituted analogue at the same position (A9) that has the52230 | RSC Adv., 2017, 7, 52227–52237same potency against S. aureus but slightly reduced potency
(MIC ¼ 7.8 mg mL1) against Gram-negative E. coli. The series B
thieno[3,2-d]pyrimidine analogues also showed some activity
against both strains of bacteria, but they were less active than
their corresponding quinazoline core analogues in general. The
SAR observed in series B compounds is very similar to the SAR
of series A. While the replacement of the quinazoline core to
a theino[3,2-d]pyrimidine core had less eﬀect on the potency
against Gram-positive S. aureus (2–4 fold reductions), this
modication resulted in a noticeable reduction of antibacterial
activity against Gram-negative E. coli (2–32 fold reductions).
Compounds in both series C and D with an additional nitrogen
incorporated into the 5- or 8-position of the quinazoline core
showed signicantly reduced potency against both strains of
bacteria. Two compounds with p-CF3 substitutions on the N
4-
benzylamine side-chain (C5 and D5) in these two series showed
moderate activities against S. aureus (MIC ¼ 15.6 mg mL1 and
7.8 mg mL1, respectively), but no activity against E. coli.
The MIC assay was used to evaluate the eight most active
compounds against S. aureus (as described above) namely, A4,
A5, A7–9, A11, B5 and, B9 against a strain of MRSA. MICs of
these selected compounds against MRSA were only two to four
folds higher than the corresponding MICs against the suscep-
tible strain of S. aureus. The MIC diﬀerence seen with this group
of compounds is similar to the MIC diﬀerences seen with the
two positive controls, i.e. Noroxacin and vancomycin (2–3
folds), but is signicantly less than that seen with methicillin
(16 folds). These results suggest that this new class of
compound has minimal cross resistance with this strain of
MRSA although further studies are required to formally conrm
this using a broader range of MRSA lines with unique and well
characterized resistance mechanisms. The most potent
compound against this strain of MRSA was A5, the p-CF3
substituted analogue from series A.
In order to extend our understanding of the antibacterial
activities of this class of compounds, the same group of eight
active compounds from series A and B were also tested against
additional strains of Gram-positive and Gram-negative bacteria,
namely S. epidermidis and S. typhimurium using the MIC assay.
Overall the antibacterial activities of these eight selected
compounds against these additional bacterial lines matched
very well with those against S. aureus and E. coli (Table 2). Most
of the tested compounds showed good activities against Gram-
positive S. epidermidis at similar levels to those observed with S.
aureus, but their potency against Gram-negative S. typhimurium
was considerably lower than their potency against other tested
strains of bacteria. Both quinazoline analogues with CF3
substituted at either ortho- or para-positions in the N4-benzyl-
amine side-chain (A4 and A5) were the most potent compounds
from the assays against S. epidermidis and S. typhimurium with
MIC ¼ 3.9 mg mL1 and 15.6 mg mL1, respectively.Physicochemical properties and in vitro metabolic stability
studies
Along with the SAR studies of these compounds, selected
derivatives were also evaluated for their DMPK propertiesThis journal is © The Royal Society of Chemistry 2017
Table 2 Antibacterial activities of the most active compounds against
MRSA, S. epidermidis and S. typhimurium
Compound
MRSAa S. epidermidisb S. typhimuriumc
MICs (mg mL1) MICs (mg mL1) MICs (mg mL1)
A4 15.6 3.9 15.6
A5 7.8 3.9 15.6
A7 31.2 7.8 15.6
A8 15.6 7.8 62.5
A9 15.6 7.8 15.6
A11 31.2 15.6 31.2
B5 15.6 7.8 $125.0
B9 15.6 7.8 31.2
Noroxacin 0.97 1.95 #0.12
Vancomycin 1.95 3.9 $31.2
Methicillin 7.8 0.24 $31.2
a Methicillin-resistant Staphylococcus aureus (MRSA), ATCC 43300.
b Staphylococcus epidermidis, ATCC 12228. c Salmonella typhimurium,
CMCC 50115.
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View Article Onlineincluding physicochemical properties such as log D7.4, aqueous
solubility and plasma protein binding, and in vitro metabolic
stability against human microsome and rat hepatocytes
(Table 3). Overall, the more active compounds, such as A4, A5,
A8 and A9 showed high lipophilicity (log D7.4) and low aqueous
solubility in PBS buﬀer. Replacing the benzene ring of quina-
zoline scaﬀold with a thiophene ring (B5 vs. A5 and B9 vs. A9)
did not alter lipophilicity but increased the aqueous solubility
slightly. Incorporation of nitrogens in diﬀerent parts of the
molecules (A5 vs. A13 or D5) or replacement of CF3 group with
an OMe group (A5 vs. A11) resulted in reductions of lipophilicity
and improvement of solubility, but all manipulations resulted
in decreased antibacterial activities. Based on the available SAR
and the data of log D7.4 in Table 3, it suggested there is
a potential positive correlation between lipophilicity and anti-
bacterial activity. Compounds A4, A5, A8, A9, B5 and B9, which
have log D7.4 values higher than 4, showed good activities
against S. aureus with MICs ¼ 3.9 mg mL1. On the contrary,
compounds A7, A11 and A13, which have log D7.4 values from
3.3 to 3.6, showed a 2-fold or 8-fold less active against the sameTable 3 Physicochemical properties and in vitro metabolic stability
Compound log D7.4 Aq. Sol.
a (mM) H. Mics CLint
b (ml m
A4 4.6 0.2 9.2
A5 4.7 0.5 29
A7 3.6 27 32
A8 4.2 5 19
A9 4.3 4 36
A11 3.3 40 37
A13 3.3 17 45
B5 4.5 3.7 70
B9 4.8 11 156
D5 4.4 3 7.6
a Aqueous solubility in pH 7.4 PBS. b Human microsomes intrinsic clea
binding.
This journal is © The Royal Society of Chemistry 2017bacterium. The percentage of human plasma protein binding
for those measured compounds also showed positive correla-
tion with lipophilicity. Although the plasma protein bindings
are in the relatively high range of percentage (96.5–99.9%) it is
not uncommon for anti-infective agents. In terms of metabolic
stability, most of the quinazoline analogues showed acceptable
stability in vitro against both human microsome and rat hepa-
tocytes, and are more stable than the corresponding thieno-
pyrimidine analogues (A5 vs. B5 and A9 vs. B9). The
azaquinazoline analogue D5 had the best in vitro metabolic
stability against both human microsome and rat hepatocytes,
but this modication was not well tolerated in the antibacterial
SAR.
Conclusions
In this article, 36 N2,N4-disubstituted quinazoline-2,4-diamines
and closely related derivatives with potential antibacterial
activity were designed and synthesized. Our SAR study
demonstrated that lipophilic electron withdrawing groups,
such as triuoromethyl and chloro, in the N4-benzylamine side-
chain were benecial for antibacterial potency, while substitu-
tion at the 4-position of the benzene ring was advantageous
compared with substitutions at the 2-position. Changing the
quinazoline scaﬀold to a thieno[3,2-d]pyrimidine, series B
compounds, still showed limited antibacterial activity
compared with the corresponding quinazoline analogues.
Scaﬀold morphing to pyrido[3,2-d]pyrimidine or pyrido[2,3-d]
pyrimidine was not tolerated in the SAR and most of the
compounds bearing these two cores were signicantly less
potent than the parent quinazolines. Screens against one strain
of MRSA suggested this class of compounds had limited cross
resistance to methicillin although the exact protein target(s) for
this class of compounds needs to be further investigated against
a broader selection of MRSA bacteria. The results from the
screens against S. aureus and E. coli in the SAR study and the
additional screens against S. epidermidis and S. typhimurium
demonstrated a broad spectrum of antibacterial activity against
both Gram-positive and Gram-negative bacteria while the
potency against Gram-positive bacteria was generally higher
than the latter. The in vitro DMPK screening results suggestedin1 mg) R. Heps CLint
c (ml min1 per 106 cells) H. PPBd %
25 99.6
45 99.8
37 98.0
98 98.9
51 99.2
>300 97.4
7.8 96.5
76 99.9
217 99.8
6.5 98.5
rance. c Rat hepatocytes intrinsic clearance. d Human plasma protein
RSC Adv., 2017, 7, 52227–52237 | 52231
RSC Advances Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
0 
N
ov
em
be
r 2
01
7.
 D
ow
nl
oa
de
d 
on
 1
7/
11
/2
01
7 
14
:4
1:
29
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinethat some of the lead series A quinazolines had acceptable
metabolic stability in vitro, their physiochemical properties,
aqueous solubility in particular would need to be improved if
they were to be developed further. The most active compound
A5 showed good potency against E. coli, S. aureus, S. epidermidis,
S. typhimurium and MRSA. Although the cytotoxicity of these
series of compounds were not determined yet, the cytotoxicity of
some closed analogues were reported by our group and others
(Van Horn 2014, Devine 2015 and Johnston 2017), and there is
no obvious risk of cytotoxicity for these chemotypes in
general.25,31,32 Further investigation of cytotoxicity of selected
leads will be carried out in the next stage of optimisation and
evaluation to mitigate any potential risk in this area. The results
from this work indicate the potential of this chemical series and
directions for further investigation of this chemotype as
potential antibacterial agents.Experimental
All chemicals, reagents and solvents were obtained from
commercial sources and used without further purication. 1H
and 13C NMR spectra were recorded on a Bruker Avance III 400
MHz Superconducting Fourier system in the solvent indicated.
Chemical shis were reported in units of ppm on the delta (d)
scale and coupling constants (J) were reported in units of Hz.
Data for 1H NMR were reported as follows: chemical shi (d
ppm), multiplicity (s ¼ singlet, d ¼ doublet, t ¼ triplet, q ¼
quartet, m¼multiplet), integration and coupling constant (Hz),
while 13C NMR analyses were reported in terms of chemical
shi. Thin-layer chromatography was performed on silica gel 60
F254 aluminium sheets from Merck KGaA. Melting points were
determined by using a microscopic melting point instrument
and were uncorrected. High resolution mass spectra (HRMS)
were performed on a Bruker maXis impact system.General method for the synthesis of compounds A, B, C, D
General synthetic procedures I. One equivalent of
quinazoline-2,4-dione and three equivalents of phosphorus
pentachloride were mixed in 10 equivalents of phosphorus
oxychloride and the mixture reuxed for 6 hours under
a nitrogen atmosphere. Aer that the mixture was cooled down
to room temperature and added with ice in the amount of 10–15
times the reaction volume. The solution was extracted with ethyl
acetate three times and the combined organic phase was dried
over anhydrous magnesium sulfate. The organic phase was
ltered and concentrated to give crude product under reduced
pressure. The crude product was puried by ash chromatog-
raphy with petroleum ether and ethyl acetate.
General synthesis procedure II. Benzylamine (1.2 equivalent)
and triethylamine (2 equivalent) were mixed with 1 equivalent
of 2,4-dichloroquinazoline in tetrahydrofuran and stirred
overnight at room temperature, aer that it was concentrated
under reduced pressure. The remaining residue was puried by
ash chromatography with petroleum ether and ethyl acetate.
General synthesis procedure III. Isopropylamine (4 equiva-
lent) and 4-benzylamino-substituted 2-chloroquinazoline (152232 | RSC Adv., 2017, 7, 52227–52237equivalent) were mixed in 5 mL 1,4-dioxane in a high pressure
reactor and heated to 120 C for 48 h. The high pressure reactor
was cooled down and the solution was concentrated under
reduced pressure. The remaining residue was puried by ash
chromatography with dichloromethane and methanol.
A1 N4-(4-Cyanobenzyl)-N2-isopropylquinazoline-2,4-diamine.
Yellow solid; yield, 75%; Rf ¼ 0.36 (9 : 1 dichloromethane to
methanol); 1H NMR (400MHz, DMSO-d6) d 10.35 (s, 1H), 8.38 (s,
1H), 7.80 (d, J ¼ 8.3 Hz, 2H), 7.78–7.72 (m, 1H), 7.59 (d, J ¼
8.2 Hz, 2H), 7.37 (s, 1H), 4.84 (d, J ¼ 5.5 Hz, 2H), 4.06 (s, 1H),
1.08 (s, 6H). 13C NMR (100 MHz, DMSO-d6) d 159.90, 158.94,
144.21, 139.90, 138.89, 135.05, 132.28, 128.26, 128.17, 124.24,
123.70, 118.75, 109.73, 62.76, 42.89, 22.03. HRMS: m/z calcd for
C19H20N5 [M + H]
+ 318.1713; found 318.1719. Melting point
257–260 C.
A2 N2-Isopropyl-N4-(2-(methylsulfonyl)benzyl)quinazoline-2,4-
diamine. Brown solid; yield, 49%; Rf ¼ 0.42 (9 : 1 dichloro-
methane to methanol); 1H NMR (400 MHz, CDCl3) d 8.04 (dd, J
¼ 7.9, 1.3 Hz, 1H), 7.71 (dd, J ¼ 7.6, 0.8 Hz, 1H), 7.64–7.56 (m,
2H), 7.55–7.47 (m, 2H), 7.39 (d, J ¼ 8.0 Hz, 1H), 7.14–7.08 (m,
1H), 5.15 (d, J ¼ 5.6 Hz, 2H), 4.29 (m, 1H), 3.18 (s, 3H), 1.27 (d, J
¼ 6.5 Hz, 6H). 13C NMR (100 MHz, CDCl3) d 160.11, 156.10,
146.37, 137.59, 137.55, 133.57, 133.36, 129.09, 129.02, 127.57,
122.05, 122.00, 120.69, 109.96, 43.48, 42.45, 41.53, 21.67. HRMS:
m/z calcd for C19H23N4O2S [M + H]
+ 371.1536; found 371.1540.
Melting point 171–173 C.
A3 N2-Isopropyl-N4-(4-(methylsulfonyl)benzyl)quinazoline-2,4-
diamine. Brown solid; yield, 53%; Rf ¼ 0.39 (9 : 1 dichloro-
methane to methanol); 1H NMR (400 MHz, CDCl3) d 8.01 (d, J ¼
6.9 Hz, 1H), 7.73 (d, J ¼ 8.3 Hz, 2H), 7.50–7.47 (m, 2H), 7.46 (d, J
¼ 7.2 Hz 1H), 7.32 (d, J ¼ 8.3 Hz, 1H), 7.07 (t, J ¼ 7.6 Hz, 1H),
4.85 (s, 2H), 4.07 (m, 1H), 2.97 (s, 3H), 1.109 (d, J ¼ 6.4 Hz 6H).
13C NMR (100 MHz, CDCl3) d 160.52, 155.15, 151.64, 145.21,
139.02, 134.17, 128.10, 127.42, 122.94, 122.67, 119.93, 110.00,
44.37, 44.11, 43.14, 22.25. HRMS: m/z calcd for C19H23N4O2S [M
+ H]+ 371.1536; found 371.1539. Melting point 175–177 C.
A4 N2-Isopropyl-N4-(2-(triuoromethyl)benzyl)quinazoline-2,4-
diamine. Yellow solid; yield, 26%; Rf ¼ 0.29 (9 : 1 dichloro-
methane to methanol); 1H NMR (400 MHz, DMSO-d6) d 10.01 (s,
1H), 8.35 (s, 1H), 7.76 (d, J ¼ 7.8 Hz, 1H), 7.74 (d, J ¼ 10.0 Hz,
1H), 7.61 (t, J ¼ 7.5 Hz, 1H), 7.50 (d, J ¼ 8.1 Hz, 1H), 7.47 (d, J ¼
7.6 Hz, 1H), 7.33 (s, 1H), 4.95 (d, J ¼ 4.4 Hz, 2H), 4.01–3.83 (m,
1H), 1.02 (dd, J¼ 22.3, 15.7 Hz, 6H). 13C NMR (100 MHz, DMSO-
d6) d 163.46, 162.50, 160.05, 150.15, 138.99, 136.68, 136.03,
132.66, 131.96, 127.73, 127.34, 126.61, 126.15, 125.85, 125.80,
123.17, 42.54, 41.04, 21.93. HRMS: m/z calcd for C19H20F3N4 [M
+ H]+ 361.1635; found 361.1639. Melting point 231–233 C.
A5 N2-Isopropyl-N4-(4-(triuoromethyl)benzyl)quinazoline-2,4-
diamine. Yellow solid; yield, 19%; Rf ¼ 0.47 (9 : 1 dichloro-
methane to methanol); 1H NMR (400 MHz, CDCl3) d 7.65 (d, J ¼
8.0 Hz, 1H), 7.52 (t, J¼ 5.6 Hz, 2H), 7.48 (dd, J¼ 6.9, 1.2 Hz, 1H),
7.42 (d, J ¼ 4.5 Hz, 2H), 7.41 (s, 1H), 7.07–7.00 (m, 1H), 6.62 (s,
1H), 4.82 (d, J ¼ 5.0 Hz, 3H), 4.17 (m, 1H), 1.14 (d, J ¼ 6.5 Hz,
6H). 13C NMR (100 MHz, CDCl3) d 160.21, 158.84, 151.97,
143.19, 133.03, 129.75, 127.92, 125.65, 125.29, 122.92, 121.17,
121.01, 110.72, 44.59, 42.88, 23.26. HRMS: m/z calcd forThis journal is © The Royal Society of Chemistry 2017
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View Article OnlineC19H20F3N4 [M + H]
+ 361.1635; found 361.1639. Melting point
69–71 C.
A6 N4-(2-Fluorobenzyl)-N2-isopropylquinazoline-2,4-diamine.
Yellow oil; yield, 89%; Rf ¼ 0.32 (9 : 1 dichloromethane to
methanol); 1H NMR (400 MHz, CDCl3) d 8.04 (d, J ¼ 5.6 Hz, 1H),
7.51 (t, J¼ 7.7 Hz, 1H), 7.36 (t, J¼ 7.1 Hz, 2H), 7.19 (d, J¼ 7.8 Hz,
1H), 7.17 (dd, J¼ 4.7, 2.8 Hz, 1H), 7.05–7.00 (m, 1H), 6.98 (d, J¼
10.0 Hz, 1H), 4.86 (d, J ¼ 3.5 Hz, 2H), 4.14 (ddd, J ¼ 18.0, 12.2,
5.3 Hz, 3H), 1.15 (d, J ¼ 6.7 Hz, 6H). 13C NMR (100 MHz, CDCl3)
d 163.65, 162.04, 160.65, 160.43, 159.59, 152.91, 134.92, 129.74,
129.39, 124.56, 124.32, 124.11, 115.55, 109.62, 43.83, 40.46,
22.46. HRMS: m/z calcd for C18H20N4 [M + H]
+ 311.1667; found
311.1669.
A7 N4-(4-Fluorobenzyl)-N2-isopropylquinazoline-2,4-diamine.
Yellow solid; yield, 83%; Rf ¼ 0.29 (9 : 1 dichloromethane to
methanol); 1H NMR (400 MHz, CDCl3) d 9.71 (s, NH), 8.49 (s,
NH), 7.47 (t, J ¼ 7.7 Hz, 1H), 7.37 (dd, J ¼ 8.3, 5.5 Hz, 2H), 7.25
(d, J ¼ 5.7 Hz, 1H), 7.14 (t, J ¼ 7.6 Hz, 1H), 6.87 (t, J ¼ 8.6 Hz,
2H), 4.80 (s, 2H), 4.17 (m, 1H), 1.18 (d, J ¼ 6.5 Hz, 5H). 13C NMR
(100 MHz, CDCl3) d 163.51, 161.07, 160.22, 134.50, 133.60,
129.77, 129.69, 123.62, 115.66, 115.45, 109.87, 63.88, 44.75,
43.69, 22.72. HRMS: m/z calcd for C18H20N4 [M + H]
+ 311.1667;
found 311.1669. Melting point 240–243 C.
A8 N4-(2-Chlorobenzyl)-N2-isopropylquinazoline-2,4-diamine.
Yellow solid; yield, 39%; Rf ¼ 0.31 (9 : 1 dichloromethane to
methanol); 1H NMR (400 MHz, CDCl3) d 8.19–8.13 (m, 1H), 7.58
(td, J ¼ 7.2, 3.2 Hz, 1H), 7.42 (d, J ¼ 7.0 Hz, 1H), 7.37–7.27 (m,
3H), 7.21–7.15 (m, 2H), 4.90 (d, J ¼ 2.3 Hz, 2H), 4.13 (m, 1H),
1.14 (d, J ¼ 6.5 Hz 6H). 13C NMR (100 MHz, CDCl3) d 160.37,
152.21, 138.98, 135.00, 134.60, 133.02, 129.48, 128.69, 128.56,
126.88, 124.39, 123.67, 116.89, 109.49, 43.79, 43.03, 21.97.
HRMS: m/z calcd for C18H20ClN4 [M + H]
+ 327.1371; found
327.1374. Melting point 209–212 C.
A9 N4-(4-Chlorobenzyl)-N2-isopropylquinazoline-2,4-diamine.
Yellow oil; yield, 94%; Rf ¼ 0.26 (9 : 1 dichloromethane to
methanol); 1H NMR (400 MHz, CDCl3) d 8.09 (d, J ¼ 7.7 Hz, 1H),
7.49 (t, J ¼ 7.7 Hz, 1H), 7.35 (d, J ¼ 8.3 Hz, 1H), 7.29 (d, J ¼
8.4 Hz, 2H), 7.22 (d, J¼ 8.4 Hz, 2H), 7.14 (t, J¼ 7.5 Hz, 1H), 6.21–
6.09 (m, 2H), 4.76 (s, 2H), 4.14 (dt, J¼ 11.4, 5.0 Hz, 1H), 1.19 (d, J
¼ 6.5 Hz, 6H). 13C NMR (100 MHz, CDCl3) d 172.91, 160.45,
152.77, 139.19, 136.22, 134.97, 133.35, 129.25, 128.74, 124.31,
116.95, 109.75, 44.85, 43.89, 22.51. HRMS: m/z calcd for
C18H20ClN4 [M + H]
+ 327.1371; found 327.1373.
A10 N2-Isopropyl-N4-(2-methoxybenzyl)quinazoline-2,4-
diamine. White solid; yield, 70%; Rf ¼ 0.31 (9 : 1 dichloro-
methane to methanol); 1H NMR (400 MHz, CDCl3) d 7.87 (d, J ¼
7.4 Hz, 1H), 7.51 (t, J ¼ 7.7 Hz, 1H), 7.38 (d, J ¼ 8.2 Hz, 1H), 7.28
(d, J¼ 7.2 Hz 1H), 7.23 (d, J¼ 7.8 Hz, 1H), 7.18 (t, J¼ 7.6 Hz, 1H),
6.87 (d, J ¼ 6.6 Hz, 1H), 6.85 (d, J ¼ 6.6 Hz, 1H), 4.84 (d, J ¼
5.0 Hz, 2H), 4.23 (m, 6.3 Hz, 1H), 3.88 (s, 3H), 1.25 (d, J¼ 6.5 Hz,
6H). 13C NMR (100 MHz, CDCl3) d 160.09, 157.57, 134.60,
129.89, 129.42, 129.18, 125.18, 123.71, 122.98, 120.91, 120.76,
110.75, 110.58, 109.71, 55.59, 43.78, 41.41, 22.62. HRMS: m/z
calcd for C19H23N4O [M +H]
+ 323.1866; found 323.1870. Melting
point 138–140 C.
A11 N2-Isopropyl-N4-(4-methoxybenzyl)quinazoline-2,4-
diamine. Yellow solid; yield, 73%; Rf ¼ 0.31 (9 : 1This journal is © The Royal Society of Chemistry 2017dichloromethane to methanol); 1H NMR (400 MHz, CDCl3)
d 8.29 (s, 1H), 7.45 (t, J ¼ 7.7 Hz, 1H), 7.35 (d, J ¼ 8.6 Hz, 2H),
7.27 (d, J ¼ 10.2 Hz, 1H), 7.13 (t, J ¼ 7.6 Hz, 1H), 6.77 (d, J ¼
8.4 Hz, 2H), 4.78 (d, J ¼ 4.2 Hz, 2H), 4.24 (m, 1H), 3.73 (s, 3H),
1.24 (d, J ¼ 6.5 Hz, 6H). 13C NMR (100 MHz, CDCl3) d 160.18,
160.11, 159.21, 134.63, 129.80, 129.56, 129.51, 123.97, 114.26,
114.21, 114.08, 110.01, 55.41, 44.98, 43.81, 22.72. HRMS: m/z
calcd for C19H23N4O [M +H]
+ 323.1866; found 323.1869. Melting
point 208–210 C.
A12 N4-(3,4-Dimethoxybenzyl)-N2-isopropylquinazoline-2,4-
diamine. Yellow solid; yield, 15%; Rf ¼ 0.39 (9 : 1 dichloro-
methane to methanol); 1H NMR (400MHz, CDCl3) d 8.24 (s, 1H),
7.44 (t, J ¼ 7.7 Hz, 1H), 7.27 (d, J ¼ 10.7 Hz, 1H), 7.11 (t, J ¼
7.6 Hz, 1H), 7.04 (d, J ¼ 1.3 Hz, 1H), 6.95 (dd, J ¼ 8.2, 1.4 Hz,
1H), 6.74 (d, J ¼ 8.2 Hz, 1H), 4.77 (s, 2H), 4.25 (m, 1H), 3.81 (s,
3H), 3.80 (s, 3H), 1.24 (d, J ¼ 6.4 Hz, 6H). 13C NMR (100 MHz,
CDCl3) d 160.19, 154.16, 149.26, 148.68, 148.65, 134.36, 130.48,
130.02, 123.87, 123.56, 120.57, 111.85, 111.31, 110.13, 56.08,
56.05, 45.27, 43.66, 22.75. HRMS:m/z calcd for C20H25N4O2 [M +
H]+ 353.1972; found 353.1976. Melting point 192–194 C.
A13 N2-Isopropyl-N4-((6-(triuoromethyl)pyridin-3-yl)methyl)
quinazoline-2,4-diamine. Yellow solid; yield, 23%; Rf¼ 0.39 (9 : 1
dichloromethane to methanol); 1H NMR (400 MHz, CD3OD)
d 8.78 (s, 1H), 8.08 (d, J ¼ 6.3 Hz, 1H), 8.07 (s, 1H), 7.79 (d, J ¼
8.1 Hz, 1H), 7.70 (t, J ¼ 7.7 Hz, 1H), 7.43 (d, J ¼ 8.1 Hz, 1H), 7.33
(t, J ¼ 7.7 Hz, 1H), 4.95 (s, 2H), 4.12 (dq, J ¼ 12.5, 6.3 Hz, 1H),
1.17 (d, J ¼ 6.4 Hz, 6H). 13C NMR (101 MHz, CD3OD) d 162.08,
155.98, 150.39, 147.70, 144.62, 139.76, 138.25, 135.77, 124.75,
124.37, 121.72, 121.70, 120.28, 111.44, 44.59, 43.34, 22.71.
HRMS: m/z calcd for C19H20F3N4 [M + H]
+ 362.1587; found
362.1590. Melting point 202–205 C.
B1 N4-(4-Cyanobenzyl)-N2-isopropylthieno[3,2-d]pyrimidine-2,4-
diamine. Yellow oil; yield, 61%; Rf¼ 0.31 (9 : 1 dichloromethane
to methanol); 1H NMR (400 MHz, CDCl3) d 7.63–7.58 (m, 2H),
7.56 (d, J ¼ 5.3 Hz, 1H), 7.46 (d, J ¼ 8.4 Hz, 2H), 7.11 (d, J ¼
5.3 Hz, 1H), 5.43 (s, NH), 4.96 (s, NH), 4.84 (d, J ¼ 5.8 Hz, 2H),
4.07 (m, 1H), 1.16 (d, J¼ 6.5 Hz, 6H). 13C NMR (100MHz, CDCl3)
d 161.09, 160.16, 157.48, 144.78, 132.52, 131.18, 128.13, 123.67,
118.88, 111.28, 106.04, 44.43, 43.23, 23.13. HRMS: m/z calcd for
C17H17N5S [M + H]
+ 324.1277; found 324.1281.
B2 N2-Isopropyl-N4-(2-(methylsulfonyl)benzyl)thieno[3,2-d]
pyrimidine-2,4-diamine. Yellow oil; yield, 38%; Rf ¼ 0.53 (9 : 1
dichloromethane to methanol); 1H NMR (400 MHz, CDCl3)
d 8.03–7.99 (m, 1H), 7.72 (d, J ¼ 7.5 Hz, 1H), 7.56 (t, J ¼ 7.4 Hz,
1H), 7.50 (d, J ¼ 5.3 Hz, 1H), 7.44 (t, J ¼ 7.6 Hz, 1H), 7.04 (d, J ¼
5.3 Hz, 1H), 5.88 (s, 1H), 5.10 (d, J ¼ 6.3 Hz, 2H), 4.70 (d, J ¼
8.0 Hz, 1H), 4.17 (dq, J¼ 13.0, 6.5 Hz, 1H), 3.14 (s, 3H), 1.20 (d, J
¼ 6.5 Hz, 6H). 13C NMR (100 MHz, CDCl3) d 161.70, 160.53,
157.18, 138.64, 138.40, 134.08, 131.84, 130.89, 129.79, 128.40,
123.72, 106.24, 45.10, 42.99, 42.05, 23.21. HRMS: m/z calcd for
C17H20N2NaO2S2 [M + Na]
+ 399.0920; found 399.0925.
B3 N2-Isopropyl-N4-(4-(methylsulfonyl)benzyl)thieno[3,2-d]
pyrimidine-2,4-diamine. Yellow oil; yield, 31%; Rf ¼ 0.56 (9 : 1
dichloromethane to methanol); 1H NMR (400 MHz, CDCl3)
d 7.80 (d, J ¼ 8.3 Hz, 2H), 7.52 (d, J ¼ 5.3 Hz, 1H), 7.49 (d, J ¼
8.2 Hz, 2H), 7.07 (d, J ¼ 5.3 Hz, 1H), 5.82 (s, 1H), 4.82 (d, J ¼
5.9 Hz, 2H), 4.75 (d, J ¼ 7.9 Hz, 1H), 4.05 (dq, J ¼ 13.1, 6.5 Hz,RSC Adv., 2017, 7, 52227–52237 | 52233
RSC Advances Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
0 
N
ov
em
be
r 2
01
7.
 D
ow
nl
oa
de
d 
on
 1
7/
11
/2
01
7 
14
:4
1:
29
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online1H), 3.00 (s, 3H), 1.12 (d, J ¼ 6.5 Hz, 6H). 13C NMR (100 MHz,
CDCl3) d 161.70, 160.46, 157.44, 146.04, 139.18, 130.98, 128.27,
127.59, 123.78, 106.06, 44.61, 44.08, 43.05, 23.12. HRMS: m/z
calcd for C17H20N2NaO2S2 [M + Na]
+ 399.0920; found 399.0924.
B4 N2-Isopropyl-N4-(2-(triuoromethyl)benzyl)thieno[3,2-d]
pyrimidine-2,4-diamine. Yellow solid; yield, 39%; Rf ¼ 0.33 (9 : 1
dichloromethane to methanol); 1H NMR (400 MHz, CD3OD)
d 7.77 (d, J ¼ 5.4 Hz, 1H), 7.68 (d, J ¼ 7.7 Hz, 1H), 7.52 (d, J ¼
4.3 Hz, 2H), 7.38 (dt, J¼ 8.1, 4.1 Hz, 1H), 7.03 (d, J¼ 5.4 Hz, 1H),
4.95 (s, 2H), 4.00–3.89 (m, 1H), 1.04 (d, J¼ 6.5 Hz, 6H). 13C NMR
(100 MHz, CD3OD) d 161.85, 161.69, 159.04, 139.67, 133.28,
133.27, 132.88, 128.90, 127.95, 126.81, 123.49, 107.34, 43.87,
41.71, 23.02. HRMS: m/z calcd for C17H18F3N4S [M + H]
+
367.1199; found 367.1203. Melting point 135–137 C.
B5 N2-Isopropyl-N4-(4-(triuoromethyl)benzyl)thieno[3,2-d]
pyrimidine-2,4-diamine. Brown solid; yield, 47%; Rf ¼ 0.31 (9 : 1
dichloromethane to methanol); 1H NMR (400 MHz, CDCl3)
d 7.53 (d, J ¼ 8.2 Hz, 2H), 7.50 (d, J ¼ 5.3 Hz, 1H), 7.43 (d, J ¼
8.1 Hz, 2H), 7.07 (d, J ¼ 5.3 Hz, 1H), 5.97 (s, 1H), 5.14 (s, 1H),
4.81 (d, J ¼ 5.6 Hz, 2H), 4.09 (dq, J ¼ 13.2, 6.5 Hz, 1H), 1.15 (d, J
¼ 6.5 Hz, 6H). 13C NMR (100 MHz, CDCl3) d 161.49, 160.45,
157.54, 143.25, 130.91, 129.96, 127.89, 125.69, 123.81, 122.91,
105.96, 44.39, 43.17, 23.16. HRMS: m/z calcd for C17H18F3N4NaS
[M + Na]+ 389.1018; found 389.1016. Melting point 62–64 C.
B6 N4-(2-Fluorobenzyl)-N2-isopropylthieno[3,2-d]pyrimidine-
2,4-diamine. Yellow oil; yield, 49%; Rf ¼ 0.51 (9 : 1 dichloro-
methane to methanol); 1H NMR (400 MHz, CDCl3) d 7.50 (d, J ¼
5.3 Hz, 1H), 7.38 (t, J ¼ 7.6 Hz, 1H), 7.23 (m, 1H), 7.10–7.01 (m,
3H), 5.54 (s, NH), 5.16 (s, NH), 4.83 (d, J¼ 5.3 Hz, 2H), 4.16 (td, J
¼ 13.0, 6.5 Hz, 1H), 1.20 (d, J ¼ 6.5 Hz, 6H). 13C NMR (100 MHz,
CDCl3) d 162.35, 159.96, 157.55, 130.98, 130.01, 129.21, 125.82,
124.28, 123.25, 115.56, 115.35, 106.21, 43.19, 38.67, 23.14.
HRMS: m/z calcd for C16H18FN4S [M + H]
+ 317.1231; found
317.1234.
B7 N4-(4-Fluorobenzyl)-N2-isopropylthieno[3,2-d]pyrimidine-
2,4-diamine. Yellow oil; yield, 58%; Rf ¼ 0.56 (9 : 1 dichloro-
methane to methanol); 1H NMR (400 MHz, CDCl3) d 7.48 (dd, J
¼ 5.3, 0.6 Hz, 1H), 7.29 (dd, J ¼ 8.2, 5.5 Hz, 2H), 7.04 (d, J ¼
5.3 Hz, 1H), 6.96 (t, J¼ 8.3 Hz, 2H), 5.94 (s, 1H), 5.06 (s, 1H), 4.71
(d, J ¼ 4.6 Hz, 2H), 4.13 (td, J ¼ 13.4, 6.5 Hz, 1H), 1.17 (d, J ¼
6.4 Hz, 6H). 13C NMR (100MHz, CDCl3) d 163.24, 160.80, 159.34,
157.42, 134.63, 131.31, 129.40, 129.32, 122.55, 115.30, 106.33,
43.95, 43.12, 22.97. HRMS: m/z calcd for C16H18FN4S [M + H]
+
317.1231; found 317.1234.
B8 N4-(2-Chlorobenzyl)-N2-isopropylthieno[3,2-d]pyrimidine-
2,4-diamine. Yellow oil; yield, 28%; Rf ¼ 0.33 (9 : 1 dichloro-
methane to methanol); 1H NMR (400 MHz, CDCl3) d 7.48 (d, J ¼
5.3 Hz, 1H), 7.39 (dd, J ¼ 5.0, 4.2 Hz, 1H), 7.34 (dd, J ¼ 5.8,
3.5 Hz, 1H), 7.19–7.17 (m, 1H), 7.16 (d, J ¼ 5.1 Hz, 1H), 7.06 (d, J
¼ 5.3 Hz, 1H), 4.84 (d, J ¼ 5.9 Hz, 2H), 4.13 (dq, J ¼ 19.5, 6.5 Hz,
1H), 1.16 (d, J ¼ 6.5 Hz, 6H). 13C NMR (100 MHz, CDCl3)
d 160.61, 160.09, 157.43, 136.19, 133.37, 130.89, 129.56, 129.45,
128.60, 126.89, 123.30, 106.14, 43.05, 42.46, 23.06. HRMS: m/z
calcd for C16H18ClN4S [M + H]
+ 333.0935; found 333.0937.
B9 N4-(4-Chlorobenzyl)-N2-isopropylthieno[3,2-d]pyrimidine-
2,4-diamine. Yellow oil; yield, 50%; Rf ¼ 0.38 (9 : 1 dichloro-
methane to methanol); 1H NMR (400 MHz, CDCl3) d 7.52 (d, J ¼52234 | RSC Adv., 2017, 7, 52227–522375.3 Hz, 1H), 7.32–7.24 (m, 4H), 7.09 (d, J ¼ 5.3 Hz, 1H), 5.65 (b,
1H), 5.32 (b, 1H), 4.74 (d, J ¼ 5.6 Hz, 2H), 4.14 (dq, J ¼ 13.1,
6.5 Hz, 1H), 1.20 (d, J ¼ 6.5 Hz, 6H). 13C NMR (100 MHz, CDCl3)
d 161.77, 160.61, 157.46, 137.62, 133.07, 130.67, 129.07, 128.72,
123.86, 106.00, 44.02, 43.03, 23.18. HRMS: m/z calcd for
C16H18ClN4S [M + H]
+ 333.0935; found 333.0938.
B10 N2-Isopropyl-N4-(2-methoxybenzyl)thieno[3,2-d]pyrimidine-
2,4-diamine. Yellow solid; yield, 37%; Rf ¼ 0.31 (9 : 1 dichloro-
methane to methanol); 1H NMR (400 MHz, CDCl3) d 7.47 (d, J ¼
5.3 Hz, 1H), 7.34 (dd, J¼ 7.4, 1.3 Hz, 1H), 7.28–7.22 (m, 1H), 7.07
(d, J ¼ 5.3 Hz, 1H), 6.91 (d, J ¼ 7.4 Hz, 1H), 6.88 (d, J ¼ 7.9 Hz,
1H), 5.42 (s, 1H), 4.82 (d, J¼ 7.8 Hz, 1H), 4.78 (d, J¼ 5.8 Hz, 2H),
4.22 (qd, J ¼ 13.0, 6.5 Hz, 1H), 3.86 (s, 3H), 1.23 (d, J ¼ 6.5 Hz,
6H). 13C NMR (100 MHz, CDCl3) d 161.31, 160.61, 157.71,
157.67, 130.25, 129.75, 128.80, 126.80, 123.81, 120.64, 110.49,
106.25, 55.41, 43.02, 40.55, 23.23. HRMS: m/z calcd for
C17H21N4OS [M + H]
+ 329.1431; found 329.1434. Melting point
60–62 C.
B11 N2-Isopropyl-N4-(4-methoxybenzyl)thieno[3,2-d]pyrimidine-
2,4-diamine. Yellow oil; yield, 51%; Rf ¼ 0.22 (9 : 1 dichloro-
methane to methanol); 1H NMR (400 MHz, CDCl3) d 7.49 (d, J ¼
5.3 Hz, 1H), 7.29 (d, J¼ 8.5 Hz, 2H), 7.09 (d, J¼ 5.3 Hz, 1H), 6.86
(d, J¼ 8.6 Hz, 2H), 5.17 (s, 1H), 4.77 (d, J¼ 7.8 Hz, 1H), 4.70 (d, J
¼ 5.5 Hz, 2H), 4.20 (m, 1H), 3.79 (s, 3H), 1.22 (d, J¼ 6.5 Hz, 6H).
13C NMR (100 MHz, CDCl3) d 160.71, 159.18, 157.54, 131.00,
130.45, 129.29, 123.97, 114.20, 106.10, 55.41, 44.42, 43.08,
23.27. HRMS: m/z calcd for C17H21N4OS [M + H]
+ 329.1431;
found 329.1432.
B12 N4-(3,4-Dimethoxybenzyl)-N2-isopropylthieno[3,2-d]pyrimi-
dine-2,4-diamine. Yellow solid; yield, 51%; Rf ¼ 0.24 (9 : 1
dichloromethane to methanol); 1H NMR (400 MHz, CDCl3)
d 7.52 (d, J ¼ 5.3 Hz, 1H), 7.10 (d, J ¼ 5.3 Hz, 1H), 6.92 (m, 2H),
6.86–6.81 (m, 1H), 5.05 (s, 1H), 4.83 (s, 1H), 4.71 (d, J ¼ 5.4 Hz,
2H), 4.21 (td, J¼ 13.1, 6.5 Hz, 1H), 3.87 (s, 3H), 3.85 (s, 3H), 1.24
(d, J ¼ 6.5 Hz, 6H). 13C NMR (100 MHz, CDCl3) d 161.33, 160.52,
157.58, 149.40, 148.77, 131.41, 130.66, 123.88, 120.37, 111.54,
111.52, 106.15, 56.14, 56.07, 44.95, 43.18, 23.28. HRMS: m/z
calcd for C18H23N4O2S [M + H]
+ 359.1536; found 359.1542.
Melting point 134–136 C.
B13 N2-Isopropyl-N4-((6-(triuoromethyl)pyridin-3-yl)methyl)
thieno[3,2-d]pyrimidine-2,4-diamine. Yellow oil; yield, 46%; Rf ¼
0.29 (9 : 1 dichloromethane to methanol); 1H NMR (400 MHz,
CDCl3) d 8.71 (s, 1H), 7.85 (d, J¼ 7.1 Hz, 1H), 7.60 (d, J¼ 8.1 Hz,
1H), 7.53 (d, J¼ 5.3 Hz, 1H), 7.08 (d, J¼ 5.3 Hz, 1H), 5.69 (s, 1H),
4.84 (d, J ¼ 5.7 Hz, 2H), 4.77 (d, J ¼ 7.6 Hz, 1H), 4.05 (m, 1H),
1.14 (d, J ¼ 6.5 Hz, 6H). 13C NMR (101 MHz, CDCl3) d 161.85,
160.44, 157.36, 149.41, 147.19, 138.42, 136.49, 131.14, 123.86,
123.03, 120.39, 106.02, 43.16, 41.96, 23.13. HRMS: m/z calcd for
C16H16F3N5NaS [M + Na]
+ 390.0971; found 390.0973.
C1 N4-(4-Cyanobenzyl)-N2-isopropylpyrido[3,2-d]pyrimidine-
2,4-diamine. Yellow oil; yield, 62%; Rf ¼ 0.56 (9 : 1 dichloro-
methane to methanol); 1H NMR (400 MHz, CDCl3) d 8.28 (d, J ¼
3.4 Hz, 1H), 7.68 (d, J¼ 7.5 Hz, 1H), 7.57 (d, J¼ 7.9 Hz, 2H), 7.43
(d, J ¼ 7.0 Hz, 2H), 7.40–7.30 (m, 1H), 5.19 (s, 1H), 4.80 (d, J ¼
5.9 Hz, 2H), 4.17 (m, 1H), 1.18 (d, J ¼ 5.8 Hz, 6H). 13C NMR (100
MHz, CDCl3) d 159.91, 158.77, 146.89, 144.35, 142.89, 132.24,
128.75, 127.98, 127.71, 118.75, 110.90, 72.69, 43.85, 42.83,This journal is © The Royal Society of Chemistry 2017
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View Article Online23.01. HRMS: m/z calcd for C18H19N6 [M + H]
+ 319.1666; found
319.1669.
C2 N2-Isopropyl-N4-(2-(methylsulfonyl)benzyl)pyrido[3,2-d]
pyrimidine-2,4-diamine. White solid; yield, 71%; Rf ¼ 0.49 (9 : 1
dichloromethane to methanol); 1H NMR (400 MHz, CDCl3)
d 8.30 (d, J ¼ 4.2 Hz, 1H), 8.05 (d, J ¼ 7.9 Hz, 1H), 7.75 (s, NH),
7.72 (d, J ¼ 7.7 Hz, 1H), 7.65 (d, J ¼ 8.4 Hz, 1H), 7.59 (t, J ¼
7.5 Hz, 1H), 7.48 (t, J¼ 7.6 Hz, 1H), 7.41 (dd, J¼ 8.5, 4.2 Hz, 1H),
5.17 (d, J ¼ 6.5 Hz, 2H), 4.91 (s, NH), 4.28–4.18 (m, 1H), 3.17 (s,
3H), 1.24 (d, J ¼ 6.5 Hz, 6H). 13C NMR (100 MHz, CDCl3)
d 160.03, 158.90, 146.86, 143.35, 138.75, 138.43, 134.14, 132.35,
131.63, 130.08, 128.57, 127.86, 72.93, 45.27, 43.08, 42.06, 23.32.
HRMS: m/z calcd for C18H22N5O2S [M + H]
+ 372.1489; found
372.1495. Melting point 161–162 C.
C3 N2-Isopropyl-N4-(4-(methylsulfonyl)benzyl)pyrido[3,2-d]
pyrimidine-2,4-diamine. Yellow oil; yield, 62%; Rf ¼ 0.50 (9 : 1
dichloromethane to methanol); 1H NMR (400 MHz, CDCl3)
d 8.32–8.28 (m, 1H), 7.90 (d, J ¼ 8.3 Hz, 2H), 7.70 (d, J ¼ 8.4 Hz,
1H), 7.58 (d, J ¼ 8.1 Hz, 2H), 7.44 (dd, J ¼ 8.5, 4.2 Hz, 1H), 4.87
(d, J ¼ 6.2 Hz, 2H), 4.18 (dt, J ¼ 13.4, 6.7 Hz, 1H), 3.03 (s, 3H),
1.21 (d, J ¼ 6.5 Hz, 6H). 13C NMR (100 MHz, CDCl3) d 160.00,
158.51, 145.20, 143.20, 139.61, 132.14, 128.36, 127.92, 127.78,
127.71, 72.80, 44.57, 43.91, 43.02, 23.06. HRMS: m/z calcd for
C18H22N5O2S [M + H]
+ 372.1489; found 372.1491.
C5 N2-Isopropyl-N4-(4-(triuoromethyl)benzyl)pyrido[3,2-d]
pyrimidine-2,4-diamine. Yellow solid; yield, 91%; Rf ¼ 0.55 (9 : 1
dichloromethane to methanol); 1H NMR (400 MHz, CDCl3)
d 8.31 (d, J ¼ 4.2 Hz, 1H), 7.72 (d, J ¼ 8.5 Hz, 1H), 7.60 (d, J ¼
8.1 Hz, 2H), 7.50 (d, J ¼ 8.0 Hz, 2H), 7.45 (dd, J ¼ 8.5, 4.2 Hz,
1H), 4.85 (d, J ¼ 6.1 Hz, 2H), 4.21 (dq, J ¼ 13.4, 6.7 Hz, 1H), 1.23
(d, J ¼ 6.5 Hz, 6H). 13C NMR (101 MHz, CDCl3) d 160.00, 158.03,
143.44, 142.43, 130.35, 128.06, 127.98, 127.88, 125.57, 122.78,
72.81, 44.08, 43.19, 22.99. HRMS: m/z calcd for C18H19F3N5 [M +
H]+ 362.1587; found 362.1595. Melting point 92–94 C.
C13 N2-Isopropyl-N4-((6-(triuoromethyl)pyridin-3-yl)methyl)
pyrido[3,2-d]pyrimidine-2,4-diamine. Yellow solid; yield, 45%; Rf
¼ 0.54 (9 : 1 dichloromethane to methanol); 1H NMR (400 MHz,
CDCl3) d 8.77 (s, 1H), 8.28 (dd, J ¼ 4.2, 1.1 Hz, 1H), 7.88 (d, J ¼
7.9 Hz, 1H), 7.68 (d, J¼ 8.4 Hz, 1H), 7.63 (d, J¼ 8.1 Hz, 1H), 7.43
(dd, J ¼ 8.5, 4.2 Hz, 1H), 4.94 (s, 1H), 4.85 (d, J ¼ 6.2 Hz, 2H),
4.17 (d, J ¼ 6.3 Hz, 1H), 1.20 (d, J ¼ 6.4 Hz, 6H). 13C NMR (101
MHz, CDCl3) d 160.09, 158.83, 149.61, 147.54, 147.20, 147.10,
143.21, 137.97, 136.52, 132.68, 127.99, 123.05, 120.47, 43.08,
41.71, 23.19. HRMS: m/z calcd for C17H18F3N6 [M + H]
+
363.1540; found 363.1546. Melting point 111–113 C.
D1 N4-(4-Cyanobenzyl)-N2-isopropylpyrido[2,3-d]pyrimidine-
2,4-diamine. Yellow oil; yield, 24%; Rf ¼ 0.32 (9 : 1 dichloro-
methane to methanol); 1H NMR (400 MHz, CD3OD) d 8.53 (dd, J
¼ 4.5, 1.6 Hz, 1H), 8.27 (d, J ¼ 7.7 Hz, 1H), 7.59 (d, J ¼ 8.1 Hz,
2H), 7.47 (d, J ¼ 8.2 Hz, 2H), 7.00 (dd, J ¼ 8.0, 4.6 Hz, 1H), 4.77
(s, 2H), 4.11 (s, 1H), 3.28–3.26 (m, 1H), 1.12 (d, J ¼ 23.6 Hz, 6H).
13C NMR (101 MHz, CD3OD) d 162.49, 162.34, 161.84, 155.60,
146.66, 133.54, 133.28, 129.18, 119.76, 117.46, 111.56, 107.13,
45.26, 43.64, 23.06. HRMS: m/z calcd for C18H18N6Na [M + Na]
+
341.1485; found 341.1489.
D2 N2-Isopropyl-N4-(2-(methylsulfonyl)benzyl)pyrido[2,3-d]
pyrimidine-2,4-diamine. Yellow solid; yield, 6%; Rf ¼ 0.40 (9 : 1This journal is © The Royal Society of Chemistry 2017dichloromethane to methanol); 1H NMR (400 MHz, CD3OD)
d 8.64–8.60 (m, 1H), 8.34 (d, J ¼ 7.5 Hz, 1H), 8.05 (d, J ¼ 7.8 Hz,
1H), 7.63 (d, J ¼ 5.5 Hz, 2H), 7.51 (dd, J ¼ 10.9, 5.5 Hz, 1H), 7.10
(dd, J ¼ 7.9, 4.6 Hz, 1H), 5.22 (s, 2H), 4.18 (s, 1H), 3.31 (s, 3H),
1.12 (s, 6H). 13C NMR (101 MHz, CD3OD) d 162.64, 155.76,
151.44, 139.95, 139.49, 135.12, 133.48, 130.85, 130.57, 130.28,
130.08, 128.96, 117.56, 44.66, 30.82, 30.31, 22.99. HRMS: m/z
calcd for C18H21NaN5O2S [M + Na]
+ 394.1308; found 394.1313.
D3 N2-Isopropyl-N4-(4-(methylsulfonyl)benzyl)pyrido[2,3-d]
pyrimidine-2,4-diamine. Yellow solid; yield, 20%; Rf ¼ 0.36 (9 : 1
dichloromethane to methanol); 1H NMR (400 MHz, CD3OD)
d 8.56 (dd, J ¼ 4.6, 1.6 Hz, 1H), 8.30 (d, J ¼ 7.7 Hz, 1H), 7.84 (d, J
¼ 8.3 Hz, 2H), 7.57 (d, J ¼ 8.3 Hz, 2H), 7.02 (dd, J ¼ 8.0, 4.6 Hz,
1H), 4.82 (s, 2H), 3.30–3.27 (m, 1H), 3.04 (s, 3H), 1.14 (d, J ¼
34.1 Hz, 6H). 13C NMR (101 MHz, CD3OD) d 162.53, 162.33,
161.90, 155.62, 147.41, 140.48, 133.56, 129.21, 128.51, 117.47,
107.15, 45.16, 44.44, 43.64, 23.07. HRMS: m/z calcd for C18H21-
NaN5O2S [M + Na]
+ 394.1308; found 394.1311. Melting point
162–164 C.
D5 N2-Isopropyl-N4-(4-(triuoromethyl)benzyl)pyrido[2,3-d]
pyrimidine-2,4-diamine. Yellow solid; yield, 74%; Rf ¼ 0.47 (9 : 1
dichloromethane to methanol); 1H NMR (400 MHz, DMSO-d6)
d 8.72–8.44 (m, 1H), 8.44 (d, J¼ 42.8 Hz, 1H), 7.62 (d, J¼ 8.1 Hz,
2H), 7.52 (d, J¼ 7.9 Hz, 2H), 7.05 (d, J¼ 35.0 Hz, 1H), 4.74 (d, J¼
4.3 Hz, 2H), 4.14–3.88 (m, 1H), 1.01 (dd, J ¼ 23.4, 16.7 Hz, 6H).
13C NMR (101 MHz, DMSO-d6) d 166.89, 160.53, 144.22, 143.15,
131.44, 127.87, 127.60, 127.29, 125.65, 125.10, 122.95, 64.96,
62.77, 22.37. HRMS: m/z calcd for C18H18F3N5Na [M + Na]
+
384.1407; found 384.1410. Melting point 107–110 C.
D13 N2-Isopropyl-N4-((6-(triuoromethyl)pyridin-3-yl)methyl)
pyrido[2,3-d]pyrimidine-2,4-diamine. Yellow solid; yield, 7%; Rf¼
0.26 (9 : 1 dichloromethane to methanol); 1H NMR (400 MHz,
CD3OD) d 8.76 (s, 1H), 8.64 (s, 1H), 8.39 (s, 1H), 8.06 (d, J ¼
8.0 Hz, 1H), 7.78 (d, J ¼ 8.1 Hz, 1H), 7.17 (s, 1H), 4.90 (d, J ¼
2.4 Hz, 2H), 4.18 (d, J ¼ 8.2 Hz, 1H), 1.15 (s, 6H). 13C NMR (101
MHz, CD3OD) d 162.36, 155.77, 150.41, 147.57, 140.24, 138.24,
133.92, 130.83, 127.14, 124.43, 121.67, 121.64, 119.00, 107.13,
64.33, 43.99, 43.20, 22.95. HRMS: m/z calcd for C17H17F3N6Na
[M + Na]+ 385.1359; found 385.1366. Melting point 108–110 C.Antibacterial activities assay
Bacterial strains and growth conditions. E. coli CMCC 44102,
S. aureus ATCC 6538, S. epidermidis ATCC 12228, S. typhimurium
CMCC 50115 and MRSA ATCC 43300 used in this study were
acquired from Guangdong Microbiology Culture Center. E. coli,
S. aureus, S. epidermidis and MRSA were grown in Mueller–
Hinton Broth (MHB) and S. typhimurium was grown in tryptic
soy broth (TSB) at 37 C, and agar was added to a nal
concentration of 1.5% (w/v) for growth plates.25
Kirby–Bauer assay. These assays for antibacterial activity
were performed as reported previously.25,33 Briey, streaked
bacterial strains were put onto agar plates and incubated over-
night. A single colony was picked to inoculate into broth media
and incubated overnight. The activated broth cultures were
diluted 1 : 1000 into 5 mL of broth media. 400 mL of diluted
culture was added to an agar plate with a diameter of 120 mmRSC Adv., 2017, 7, 52227–52237 | 52235
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View Article Onlineand was coated uniformly, allowed to dry for 15 min before use.
Aer that, nine sterile lter disks with a diameter of 6 mm were
added and 5 mL of 5 mg mL1 test compound dissolved in
DMSO were dropwise added to each lter disk. Bacterial plates
were incubated overnight. The assays were performed in trip-
licate and zones of inhibition were measured in millimeters.
Microtiter MIC determination assay. Two assays were carried
out based on previous methods.25,33 The minimum inhibitory
concentrations (MIC) were determined for compounds which
showed antibacterial activity against corresponding strains.
Broth cultures were prepared as above and 1000 fold diluted
cultures were added to a sterile 96-well plate with a dosage of
200 mL per well. 5 mL compounds, with two-times gradient
dilution, were added to wells and mixed by pipetting, then, the
plates were incubated at 37 C overnight. MICs were determined
by visual inspection of minimum concentration of compound
inhibiting bacterial growth. Each concentration was performed
parallelly in triplicate to verify the MIC determinations. Pure
DMSO was used as blank control which didn't show inhibition
about bacterial growth.DMPK properties assays
The DMPK properties data described above were measured
through a high through-put platform kindly provided by
AstraZeneca U.K. The methods of the ve assays, including
log D7.4, aqueous solubility, plasma protein binding, micro-
some and hepatocyte clearance measurements has been re-
ported previously (Basarab et al., 2014 and Doyle et al., 2016)
and are described briey as below34,35.
log D7.4 Determination assay. The partition coeﬃcient
(log D) was measured by shake ask method, using 10 mM
phosphate buﬀer at pH 7.4 and n-octanol. The samples were
allowed to reach equilibrium by shaking for 1 hour at 1200 rpm,
and sample analysis was done by LC/UV, with MS for mass
conrmation.
Aqueous (thermodynamic) solubility assay. It is a shake-ask
approach that uses compounds dried from 10 mM DMSO
solutions. The dried compounds are equilibrated in an aqueous
phosphate buﬀer (pH 7.4) for 24 hours at 25 C, the portion with
the dissolved compound is then separated from the remains.
The solutions are analysed and quantied using UPLC/MS/MS.
Plasma protein binding determination assay. Human
plasma protein binding was determined from a 10 mM
compound solution in a Dianorm plasma well incubating at
37 C for 16 hours. Free fractions were calculated from ratios of
drug concentration in buﬀer and plasma wells determined by
LC-MS/MS.
In vitro hepatocyte and microsomal clearance assays. Cry-
opreserved or fresh hepatocytes were incubated with test
compounds at a nal concentration of 1 mM in incubation
medium containing 1.0  106 viable cells per mL (hepatocyte
incubations) or with a microsomal protein concentration of
1 mg mL1 + 1 mM NADPH. Incubations were performed at
37 C and samples taken at 5, 15, 30, 45, 60, 80, 100 and 120min
(hepatocytes) and 0.5, 5, 10, 15, 20 and 30 min (microsomes) for
analysis using LC-MS/MS. Peak areas were determined from52236 | RSC Adv., 2017, 7, 52227–52237extracted ion chromatograms and the in vitro half-life (t1/2) of
parent compound determined by regression analysis of the ln
percent parent disappearance vs. time curve. The in vitro
intrinsic clearance (in vitro CLint, in mLmin
1 per 106 cells or mg
protein) was determined from the slope value using the
following equation: in vitro CLint ¼ kV/N where V ¼ incubation
volume; N ¼ number of hepatocytes or protein concentration
per well.
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